Background illustration for clinical trials search

Paid Clinical Trials Princeton

Discover 1,664 paid clinical trials in Princeton, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,664

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

for

Advanced Solid Tumors, Colorectal Cancer

Location: New Brunswick NJ, Toronto, Ann Arbor MI,

Sponsor: Vividion Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06004245

Phase1, Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: New Brunswick NJ, Newark NJ, The Bronx NY, Baltimore MD,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05172245

Phase1, Recruiting

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

for

Glioblastoma (GBM)

Location: New Brunswick NJ, Summit NJ, Camden NJ, New York NY,

Sponsor: Diakonos Oncology Corporation

Sex: All

Age: 18+

Code: NCT06805305

Phase2, Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

for

Breast Cancer

Location: New Brunswick NJ, Somerville NJ, Livingston NJ,

Sponsor: Mridula George, MD

Sex: Female

Age: 60+

Code: NCT06139107

Phase1, Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for

HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,

Location: New Brunswick NJ, New York NY, Fairfax VA, Boston MA,

Sponsor: Iambic Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06253871

Phase1, Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for

Embryonal Rhabdomyosarcoma,

Location: New Brunswick NJ, Morristown NJ, Newark NJ,

Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 21

Code: NCT05304585

Phase3, Recruiting

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

for

Plasma Cell Myeloma

Location: New Brunswick NJ

Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT04211259

Early_phase1, Recruiting

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

for

Lung Cancer

Location: New Brunswick NJ, Rochester NY, Columbia MO

Sponsor: Bo Lu

Sex: All

Age: 18+

Code: NCT06410300

Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: New Brunswick NJ, Basking Ridge NJ, Middletown NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: New Brunswick NJ, Willow Grove PA, Philadelphia PA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: New Brunswick NJ, Basking Ridge NJ, Middletown NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for

B-cell Acute Lymphoblastic Leukemia,

Location: New Brunswick NJ, Philadelphia PA, New York NY,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 25

Code: NCT06395103

Phase1, Phase2, Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: New Brunswick NJ, Basking Ridge NJ, Philadelphia PA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04269902

Phase3, Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: New Brunswick NJ, Somerville NJ, Basking Ridge NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

for

Nonmuscle-invasive Bladder Cancer

Location: New Brunswick NJ, Pittsburgh PA, Middleburg Heights OH,

Sponsor: ImmVira Pharma Co. Ltd

Sex: All

Age: 18+

Code: NCT06971614

Phase2, Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

for

Endometrial Adenocarcinoma

Location: New Brunswick NJ, New York NY, Hackensack NJ,

Sponsor: Acrivon Therapeutics

Sex: Female

Age: 18+

Code: NCT05548296

Phase2, Recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for

Renal Pelvis and Ureter Urothelial Carcinoma

Location: New Brunswick NJ, Livingston NJ, Toms River NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04628767

Phase2, Phase3, Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for

Solid Tumors, Hematologic Malignancies

Location: New Brunswick NJ, Philadelphia PA, New York NY,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT03486873

Phase3, Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

for

Locoregional Recurrence,

Location: New Brunswick NJ, New York NY, Hershey PA,

Sponsor: Oana Danciu

Sex: All

Age: 18+

Code: NCT05467891

Phase2, Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

for

Squamous Cell Carcinoma of Head and Neck

Location: New Brunswick NJ, New Haven CT, Baltimore MD,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06385080

Phase1, Phase2, Recruiting

Paid Clinical Trials Princeton

Filter results

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Interested in new trials?

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer